Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial.

ABSTRACT:

Background

The Costa Rica HPV Vaccine Trial has documented cross-protection of the bivalent HPV vaccine against HPV31/33/45 up to 7 years after vaccination, even with one dose of the vaccine. However, the durability of such protection remains unknown. Here, we evaluate the efficacy of different schedules of the vaccine against HPV31/33/45 out to 11 years postvaccination, expanding to other nontargeted HPV types.

Methods

We compared the rates of HPV infection in vaccinated women with the rates in a comparable cohort of unvaccinated women. We estimated the average vaccine efficacy (VEavg) against incident infections and tested for a change in VE over time.

Results

Among 3-dose women, we observed statistically significant cross-protection against HPV31/33/45 (VEavg = 64.

SUBMITTER: Tsang SH 

PROVIDER: S-EPMC7566371 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature